AU2019393347A1 - Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome - Google Patents

Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome Download PDF

Info

Publication number
AU2019393347A1
AU2019393347A1 AU2019393347A AU2019393347A AU2019393347A1 AU 2019393347 A1 AU2019393347 A1 AU 2019393347A1 AU 2019393347 A AU2019393347 A AU 2019393347A AU 2019393347 A AU2019393347 A AU 2019393347A AU 2019393347 A1 AU2019393347 A1 AU 2019393347A1
Authority
AU
Australia
Prior art keywords
formulation
pentylphenyl
acetate
improving
histology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019393347A
Other languages
English (en)
Inventor
Frank CESARI
Lyne Gagnon
Pierre Laurin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal Biosciences Ltd
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Publication of AU2019393347A1 publication Critical patent/AU2019393347A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019393347A 2018-12-05 2019-12-05 Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome Abandoned AU2019393347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775849P 2018-12-05 2018-12-05
US62/775,849 2018-12-05
PCT/CA2019/051753 WO2020113340A1 (en) 2018-12-05 2019-12-05 Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome

Publications (1)

Publication Number Publication Date
AU2019393347A1 true AU2019393347A1 (en) 2021-07-22

Family

ID=70973699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019393347A Abandoned AU2019393347A1 (en) 2018-12-05 2019-12-05 Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome

Country Status (6)

Country Link
US (1) US20220016060A1 (https=)
EP (1) EP3890717A4 (https=)
JP (1) JP2022510436A (https=)
AU (1) AU2019393347A1 (https=)
CA (1) CA3121830A1 (https=)
WO (1) WO2020113340A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761061A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
EA022445B1 (ru) * 2009-05-04 2016-01-29 Прометик Байосайенсиз Инк. Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物

Also Published As

Publication number Publication date
WO2020113340A1 (en) 2020-06-11
CA3121830A1 (en) 2020-06-11
EP3890717A1 (en) 2021-10-13
US20220016060A1 (en) 2022-01-20
EP3890717A4 (en) 2022-08-24
JP2022510436A (ja) 2022-01-26

Similar Documents

Publication Publication Date Title
Baker et al. Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization
AU2020233626B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP6105546B2 (ja) ピラゾール誘導体及びその医薬用途
Buyse et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance
JP7494277B2 (ja) ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
TWI900606B (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
JP2014507456A (ja) メトホルミン及びｄｐｐ−４阻害剤又はｓｇｌｔ−２阻害剤を含む医薬組成物
US20200061092A1 (en) Methods and compositions for treating disorders associated with muscle weakness
US20220016060A1 (en) Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome
EP3199183A1 (en) Renal imaging agent
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
HK40051086A (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
HK40046452A (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
CN112336713A (zh) 利用达格列净治疗射血分数降低的心力衰竭的方法
Allam et al. A 77-Year-Old Female With Worsening Shortness of Breath and Leg Swelling
KR20250113341A (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비만 예방 또는 치료용 약학적 조성물
JP2011519877A (ja) インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物
CN120284970A (zh) Cb-839在制备治疗糖尿病肾脏病药物中的应用
US9517217B2 (en) Immune cell activation inhibitor and use thereof
HK40046452B (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
HK40012462B (en) Treatment of nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period